Alector to Host Mid-Year Earnings Conference Call
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company focused on immuno-neurology, has announced a conference call and webcast scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT. The event will discuss second quarter 2024 results and provide a mid-year business update. A press release detailing Q2 results will be issued before the call. The webcast will be available on Alector's investor relations website, with a 30-day replay option. Phone participants must register online to receive dial-in details and a personal PIN for access.
Alector (Nasdaq: ALEC), un'azienda biotecnologica in fase clinica focalizzata sull'immuno-neurologia, ha annunciato una conferenza telefonica e una trasmissione web prevista per mercoledì 7 agosto 2024, alle 16:30 ET/13:30 PT. L'evento discuterà i risultati del secondo trimestre 2024 e fornirà un aggiornamento aziendale di metà anno. Un comunicato stampa contenente i risultati del secondo trimestre sarà pubblicato prima della chiamata. La trasmissione web sarà disponibile sul sito delle relazioni con gli investitori di Alector, con un'opzione di replay per 30 giorni. I partecipanti telefonici devono registrarsi online per ricevere i dettagli di accesso e un PIN personale.
Alector (Nasdaq: ALEC), una empresa biotecnológica en etapa clínica centrada en la inmunoneurología, ha anunciado una conferencia telefónica y una transmisión web programadas para miércoles 7 de agosto de 2024, a las 4:30 p.m. ET/1:30 p.m. PT. El evento discutirá los resultados del segundo trimestre de 2024 y proporcionará una actualización empresarial de mitad de año. Se emitirá un comunicado de prensa detallando los resultados del segundo trimestre antes de la llamada. La transmisión web estará disponible en el sitio web de relaciones con inversionistas de Alector, con opción de repetición durante 30 días. Los participantes por teléfono deben registrarse en línea para recibir los detalles de acceso y un PIN personal.
Alector(Nasdaq: ALEC)는 면역신경학에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 8월 7일 수요일 오후 4:30 ET/오후 1:30 PT에 예정된 전화 회의 및 웹캐스트를 발표했습니다. 이 이벤트에서는 2024년 2분기 실적에 대한 논의와 중간 연도 사업 업데이트가 제공될 것입니다. 전화 회의 전에 2분기 실적에 대한 보도 자료가 발표될 예정입니다. 웹캐스트는 Alector의 투자자 관계 웹사이트에서 이용 가능하며, 30일 동안 다시 볼 수 있는 옵션이 있습니다. 전화 참여자는 접속 세부사항과 개인 PIN을 받기 위해 온라인에서 등록해야 합니다.
Alector (Nasdaq: ALEC), une entreprise de biotechnologie en phase clinique axée sur l'immunoneurologie, a annoncé une conférence téléphonique et un webinaire prévu pour mercredi 7 août 2024, à 16h30 ET/13h30 PT. Cet événement discutera des résultats du deuxième trimestre 2024 et fournira une mise à jour commerciale semestrielle. Un communiqué de presse détaillant les résultats du T2 sera publié avant l'appel. Le webinaire sera disponible sur le site web des relations avec les investisseurs d'Alector, avec une option de rediffusion de 30 jours. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les détails de connexion et un code PIN personnel.
Alector (Nasdaq: ALEC), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Immunoneurologie konzentriert, hat einen Telefonkonferenz- und Webcast-Termin für Mittwoch, den 7. August 2024, um 16:30 Uhr ET/13:30 Uhr PT angekündigt. Bei der Veranstaltung werden die Ergebnisse des zweiten Quartals 2024 besprochen und ein Halbjahresgeschäftsupdate gegeben. Eine Pressemitteilung mit den Q2-Ergebnissen wird vor dem Anruf veröffentlicht. Der Webcast ist auf der Investor Relations-Website von Alector verfügbar und bietet eine 30-tägige Wiedergabe-Option. Telefonteilnehmer müssen sich online registrieren, um die Einwahldaten und eine persönliche PIN zu erhalten.
- None.
- None.
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call.
The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
FAQ
When is Alector (ALEC) hosting its mid-year earnings conference call?
What will be discussed during Alector's (ALEC) upcoming conference call?
How can investors access Alector's (ALEC) mid-year earnings call?
Will Alector (ALEC) provide financial results before the conference call?
